<DOC>
	<DOCNO>NCT00185094</DOCNO>
	<brief_summary>To examine effect three different blood pressure medication insulin sensitivity overweight patient high blood pressure .</brief_summary>
	<brief_title>A Comparison Effect Olmesartan Medoxomil , Losartan Potassium , Atenolol Ability Overweight Patients With High Blood Pressure Respond Insulin</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Patients age 18 75 year ( inclusive ) Willingness undergo insulin clamp procedure twice Overweight obese ( BMI=2539 kg/m2 ) Subject must meet one follow two blood pressure criterion week2 week1 : Systolic blood pressure 140179 mmHg diastolic blood pressure 8599 mmHg OR Systolic blood pressure &lt; 140 mmHg diastolic blood pressure 9099 mmHg If female , must negative serum pregnancy test screen either postmenopausal , hysterectomy tubal ligation least 6 month consent childbearing potential , must practice approve measure birth control throughout study Systolic blood pressure &gt; 179 mmHg Diastolic blood pressure &gt; 99 mmHg &lt; 85 mmHg Diagnosis diabetes mellitus History myocardial infraction , percutaneous transluminal coronary revascularization , coronary artery bypass graft , unstable angina pectoris episode heart failure require hospitalization Previous history cerebrovascular accident transient ischemic attack History allergic response atenolol , losartan potassium , olmesartan medoxomil component Any serious disorder , include pulmonary , hepatic , renal , gastrointestinal ( include clinically significant malabsorption ) , uncontrolled endocrine/metabolic , hematologic/oncologic ( within last 5 year ) , neurologic , psychiatric disease , would interfere conduct study interpretation data Laboratory abnormality could compromise subject safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>